Safety Study of Recombinant Interferon Variant(PEG-IFN-SA) to Treat HCV Disease

NCT01605513 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Hepatitis C Virus

Interventions

DRUG: interferon

Sponsor

The First Hospital of Jilin University